Figure 3From: Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinomaRepresentative effector CD8+ T cell and Treg responses in 3 patients (A-C). effector/regulatory T cell ratio in all patients (D). SD, stable disease (open square), PD, progressive disease (closed square).Back to article page